Breakthrough Discovery: SLC35F2 Gene Enables Quinozen Entry into Cells

By Stayinghealthy !

 

Discovery of SLC35F2 gene reveals how Quinozen enters cells—unlocking new therapies for cancer, brain diseases, and metabolic disorders.
The SLC35F2 gene acts as the cellular gateway for Quinozen (queuosine), enabling its entry into human cells to support gene regulation and disease prevention / Pexels 



In a landmark genomics breakthrough, scientists have identified the SLC35F2 gene as the exclusive gateway for the nutrient compound queuosine (aka Quinozen) into human cells. This discovery opens new avenues in nutritional genomics, precision medicine, and potential therapies for cancer, neurodegenerative diseases, and metabolic disorders.

 What Is Quinozen?

Quinozen is a vitamin-like micronutrient derived from dietary sources—such as dairy and potatoes—and produced by beneficial gut bacteria. Humans cannot synthesize it, making external intake essential. Within cells, quinozen modifies transfer RNA (tRNA) and regulates messenger RNA (mRNA) translation, influencing protein synthesis critical for cellular repair and health.

 The SLC35F2 Gene: A Cellular Transporter

Published in PNAS, this study confirms that SLC35F2 is the sole high-affinity transporter for queuosine (Km ≈ 174 nM) and queuine (Km ≈ 67 nM) in human cells, with another lower-affinity transporter unexplained so far 0.

Localization studies via immunofluorescence show SLC35F2 on the cell membrane and Golgi apparatus—highlighting its importance in intracellular nutrient trafficking .

 Implications for Health and Disease

  • Cancer therapy: SLC35F2’s role extends to drug uptake in cancer cells, influencing chemotherapy efficacy and revealing new targets in tumor treatment .
  • Neurodegenerative diseases: By ensuring proper quinozen entry, SLC35F2 supports mRNA translation, which is vital for neuronal maintenance and brain function .
  • Metabolic stress disorders: Proper metabolic regulation depends on tRNA modifications—impeded without SLC35F2, potentially leading to metabolic imbalance .

 Precision Medicine & Nutritional Genomics

Understanding SLC35F2’s transport mechanism empowers the development of personalised therapies: tailored quinozen supplements and targeted gene modulation could optimize treatment for patients with SLC35F2 dysfunction.

 Ongoing Research & Future Directions

Key areas under active investigation:

  1. Exploring other low-affinity transporters for queuosine.
  2. Evaluating how SLC35F2 expression varies across cancer types and patient populations — Human Protein Atlas shows differential expression in renal, head‑and‑neck, and brain cancers .
  3. Clinical development of SLC35F2-modulated micronutrient therapies and analogues targeting neurodegeneration and metabolic health.

 References